Ludwig Aigner

Title: Ludwig Aigner and His Patent for Improved Leukotriene Receptor Antagonist Delivery.

Introduction

Ludwig Aigner is an inventor associated with Freilassing, Germany, and Nualtis Corp. His work includes a patent focused on improving the bioavailability of leukotriene receptor antagonists, including Montelukast.

Latest Patents

Aigner is credited with 1 patent: “Method of Treatment and Device for the Improved Bioavailability of Leukotriene Receptor Antagonists.” The patent describes an alkaline-surface-pH oral film dosage form designed to deliver the medicine to the stomach as an amorphous precipitate suspended in an aqueous medium. It also describes a film unit dosage form containing a safe and effective amount of Montelukast, formulated primarily for enteral delivery.

The disclosed approach is intended to support treatment of diseases or conditions associated with leukotriene-induced neuroinflammation, including neurodegenerative conditions. The method involves enterally administering Montelukast in a form intended to cross the blood-brain barrier.

Career Highlights

Aigner’s listed patent work connects pharmaceutical formulation and drug-delivery design. The invention centers on an oral film device and a method intended to improve the delivery and bioavailability of leukotriene receptor antagonists.

Collaborations

Aigner’s listed coworkers include Nadine Paiement and Horst G. Zerbe. The patent is associated with Nualtis Corp.

Conclusion

Ludwig Aigner’s patent describes an oral-film approach for delivering Montelukast and other leukotriene receptor antagonists, with a focus on bioavailability and potential treatment of conditions linked to neuroinflammation.